The UK has championed since the beginning of the pandemic the importance of rapid, equitable access to safe and effective vaccines. We are among the largest donors to the COVAX Advance Market Commitment (AMC), committing £548 million which leveraged through match funding $1 billion from other donors in 2020. This support to COVAX has been critical to it distributing COVID-19 vaccines to over 135 countries and economies, with its aim to provide up to 1.8 billion doses to low- and middle-income countries by early 2022. The UK has also committed to share 100 million vaccine doses by June 2022, 80% of which will go to COVAX to provide further support for countries in need.
The UK's investment in the research and development of the Oxford/AstraZeneca vaccine has been a key contribution to the global vaccination effort. So far over 500 million doses of the vaccine have been distributed worldwide at non-profit prices, with two-thirds of these going to low- and middle- income countries.